Literature DB >> 26830756

Soluble neprilysin retains catalytic activity in heart failure.

Antoni Bayes-Genis1, Timothy C Prickett2, A Mark Richards2, Jaume Barallat3, Josep Lupón1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26830756     DOI： 10.1016/j.healun.2015.12.015

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN： 1053-2498            Impact factor:   10.247


× No keyword cloud information.
  10 in total

1.  Neurohormonal Blockade in Heart Failure.

Authors:  Thomas G von Lueder; Dipak Kotecha; Dan Atar; Ingrid Hopper
Journal:  Card Fail Rev       Date:  2017-04

2.  Neprilysin levels at the acute phase of ST-elevation myocardial infarction.

Authors:  Hugo Bernelin; Nathan Mewton; Salim Si-Mohamed; Pierre Croisille; Gilles Rioufol; Eric Bonnefoy-Cudraz; Philippe Douek; Nathalie Dufay; Camille Amaz; Claire Jossan; Michel Ovize; Thomas Bochaton
Journal:  Clin Cardiol       Date:  2018-12-10       Impact factor: 2.882

3.  The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.

Authors:  Noemi Pavo; Henrike Arfsten; Anna Cho; Georg Goliasch; Philipp E Bartko; Raphael Wurm; Claudia Freitag; Heinz Gisslinger; Gabriela Kornek; Guido Strunk; Markus Raderer; Christoph Zielinski; Martin Hülsmann
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

Review 4.  Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.

Authors:  Kumaresan Ramanathan; Giri Padmanabhan
Journal:  Indian Heart J       Date:  2020-02-04

5.  Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice.

Authors:  Laale F Alawi; Sana E Emberesh; Brenda A Owuor; Harshita Chodavarapu; Rucha Fadnavis; Salim S El-Amouri; Khalid M Elased
Journal:  Physiol Rep       Date:  2020-02

6.  Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.

Authors:  Suriya Prausmüller; Henrike Arfsten; Georg Spinka; Claudia Freitag; Philipp E Bartko; Georg Goliasch; Guido Strunk; Noemi Pavo; Martin Hülsmann
Journal:  J Am Heart Assoc       Date:  2020-05-19       Impact factor: 5.501

Review 7.  Neprilysin as a Biomarker: Challenges and Opportunities.

Authors:  Noemi Pavo; Suriya Prausmüller; Philipp E Bartko; Georg Goliasch; Martin Hülsmann
Journal:  Card Fail Rev       Date:  2020-08-14

Review 8.  Biomarkers in Heart Failure with Preserved Ejection Fraction.

Authors:  Antoni Bayes-Genis; Germán Cediel; Mar Domingo; Pau Codina; Evelyn Santiago; Josep Lupón
Journal:  Card Fail Rev       Date:  2022-06-23

9.  Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.

Authors:  Akiomi Yoshihisa; Tetsuro Yokokawa; Tomofumi Misaka; Masayoshi Oikawa; Atsushi Kobayashi; Takayoshi Yamaki; Koichi Sugimoto; Hiroyuki Kunii; Kazuhiko Nakazato; Yasuchika Takeishi
Journal:  ESC Heart Fail       Date:  2019-01-25

10.  Soluble neprilysin and survival in critically ill patients.

Authors:  Max Lenz; Konstantin A Krychtiuk; Mira Brekalo; Dominik F Draxler; Noemi Pavo; Christian Hengstenberg; Kurt Huber; Martin Hülsmann; Gottfried Heinz; Johann Wojta; Walter S Speidl
Journal:  ESC Heart Fail       Date:  2022-01-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.